Compare LION & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LION | TLX |
|---|---|---|
| Founded | 1997 | 2015 |
| Country | Canada | Australia |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.2B |
| IPO Year | 2025 | N/A |
| Metric | LION | TLX |
|---|---|---|
| Price | $12.19 | $10.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | $11.14 | ★ $21.13 |
| AVG Volume (30 Days) | ★ 3.3M | 200.4K |
| Earning Date | 05-21-2026 | 08-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,195,500,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $22.79 | N/A |
| P/E Ratio | ★ N/A | $150.33 |
| Revenue Growth | ★ 7.00 | N/A |
| 52 Week Low | $5.65 | $6.28 |
| 52 Week High | $12.58 | $18.99 |
| Indicator | LION | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 66.62 | 59.54 |
| Support Level | $6.16 | $9.46 |
| Resistance Level | $12.58 | $11.28 |
| Average True Range (ATR) | 0.61 | 0.31 |
| MACD | 0.06 | -0.09 |
| Stochastic Oscillator | 84.82 | 40.38 |
Lionsgate Studios Corp is a motion picture and television studio operations aligned with the STARZ premium subscription platform to bring a varied portfolio of entertainment to consumers around the world. The group has two reportable business segments: the Motion Picture and Television Production reportable segments. Motion Picture consists of the development and production of feature films, the acquisition of North American and world-wide distribution rights. Television Production consists of the development, production, and world-wide distribution of television productions, including television series, television movies and mini-series, and non-fiction programming.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.